Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director comp.
CC transcript
EXELIXIS, INC. (EXEL) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/09/2023 8-K Quarterly results
Docs: "Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update - Total Revenues of $408.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $363.4 million -"
02/07/2023 8-K Quarterly results
Docs: "EXELIXIS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE"
08/09/2022 8-K Quarterly results
Docs: "EXELIXIS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE"
05/10/2022 8-K Quarterly results
02/17/2022 8-K Quarterly results
Docs: "EXELIXIS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE"
11/02/2021 8-K Quarterly results
Docs: "EXELIXIS ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE"
08/05/2021 8-K Quarterly results
Docs: "EXELIXIS ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE"
05/06/2021 8-K Quarterly results
02/10/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "EXELIXIS ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE"
08/06/2020 8-K Quarterly results
05/05/2020 8-K Quarterly results
02/25/2020 8-K Quarterly results
10/30/2019 8-K Quarterly results
07/31/2019 8-K Quarterly results
Docs: "EXELIXIS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenue of $240.3 Million, Cabozantinib Franchise Revenue of $193.7 Million - - GAAP Diluted EPS of $0.25, Non-GAAP Diluted EPS of $0.29 - - Conference Call and Webcast Today at 5:00 PM Eastern Time -"
05/01/2019 8-K Quarterly results
Docs: "EXELIXIS ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenue of $215.5 Million, Cabozantinib Franchise Revenue of $179.6 Million - - GAAP Diluted EPS of $0.24, Non-GAAP Diluted EPS of $0.27 - - Conference Call and Webcast Today at 5:00 PM Eastern Time -"
02/12/2019 8-K Quarterly results
11/01/2018 8-K Quarterly results
Docs: "EXELIXIS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $225.4 million - - Cabozantinib Franchise Net Product Revenues of $162.9 million - - Net Income of $126.6 million, Diluted EPS of $0.41 - - Conference Call and Webcast Today at 5:00 P.M. Eastern Daylight Time -"
08/01/2018 8-K Quarterly results
Docs: "EXELIXIS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $186.1 million, Net Income of $87.5 million, Diluted EPS of $0.28 - - Cabozantinib Franchise Net Product Revenues of $145.8 million - - Ipsen Royalty Rate Increased to 22 Percent upon Reaching $150.0 million in Cumulative Net Sales - - Conference Call and Webcast Today at 5:00 P.M. Eastern Daylight Time -"
05/02/2018 8-K Quarterly results
Docs: "EXELIXIS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $212.3 million - - Cabozantinib Franchise Net Product Revenues of $134.3 million - - Net Income of $115.9 million, Diluted EPS of $0.37 - - Conference Call and Webcast Today at 5:00 PM Eastern Time -"
02/26/2018 8-K Quarterly results
Docs: "EXELIXIS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenue of $120.1 million for the Fourth Quarter of 2017, $452.5 million for the Full Year 2017 - - Cabozantinib Franchise Net Product Revenue of $95.7 million for the Fourth Quarter of 2017, $349.0 million for the Full Year 2017 - - Diluted EPS of $0.12 per Share for the Fourth Quarter of 2017, $0.49 for the Full Year 2017 - - Conference Call and Webcast Today at 5:00 PM Eastern Time -"
11/01/2017 8-K Quarterly results
Docs: "EXELIXIS ANNOUNCES THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Cabozantinib Franchise Net Product Revenue of $96.4 million, Total Revenue of $152.5 million - - Net Income of $81.4 million, Diluted EPS of $0.26 per Share - - Conference Call and Webcast Today at 5:00 PM Eastern Time -"
08/02/2017 8-K Quarterly results
05/01/2017 8-K Form 8-K - Current report
02/27/2017 8-K Form 8-K - Current report
11/03/2016 8-K Form 8-K - Current report
08/03/2016 8-K Quarterly results
Docs: "EXELIXIS ANNOUNCES SECOND QUARTER AND YEAR TO DATE 2016 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Launch of CABOMETYX Results in Cabozantinib Franchise Sales of $31.6 Million - - Conference Call and Webcast Today at 5:00 PM Eastern Time -"
05/04/2016 8-K Form 8-K - Current report
02/29/2016 8-K Quarterly results
Docs: "EXELIXIS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2015 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Conference Call and Webcast Today at 5:00 PM Eastern Time -"
11/10/2015 8-K Quarterly results
Docs: "EXELIXIS ANNOUNCES THIRD QUARTER 2015 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Conference Call and Webcast Today at 5:00 PM Eastern Time -",
"EXELIXIS ANNOUNCES THIRD QUARTER 2015 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Conference Call and Webcast Today at 5:00 PM Eastern Time -"
08/11/2015 8-K Quarterly results
Docs: "EXELIXIS ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Conference Call and Webcast Today at 5:00 PM Eastern Time -"
04/30/2015 8-K Quarterly results
Docs: "EXELIXIS ANNOUNCES FIRST QUARTER 2015 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Conference Call and Webcast Today at 5:00 PM Eastern Time -"
02/24/2015 8-K Quarterly results
Docs: "EXELIXIS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2014 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Conference Call and Webcast Today at 5:00 PM Eastern Time -"
11/04/2014 8-K Quarterly results
Docs: "EXELIXIS ANNOUNCES THIRD QUARTER 2014 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Conference Call and Webcast Today at 5:00 PM Eastern Time -"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy